Erratum to: J Headache Pain DOI 10.1007/s10194-008-0046-6 {#Sec1}
=========================================================

This article unfortunately contained errors in two places.

1\. The two columns of data in Table [1](#Tab1){ref-type="table"} were under the wrong headings. The correct version of Table [1](#Tab1){ref-type="table"} is given here:Table 1Relative proportions of standardised medication units (SU) among different countries comparing weighted and unweighted proportionsRelative proportions of ASA consumptionUnweighted (%)Weighted by mg ASA (%)USA58.248.3Germany (West)16.019.7Canada12.210.7France9.716.7Sweden1.11.3Switzerland0.70.8Austria1.71.8Belgium0.30.6Australia0.10.1Total 9 countries100100100% = overall consumption of acetylic salicylic acid (ASA) among nine countries

2\. Incorrect percentages were given in the last paragraph of the "Results" section, immediately before the "Discussion". The corrected paragraph is as follows:

In 2005 in the prescription (Rx) group of N2B analgesics, combination products accounted for approx. 33% of all Rx analgesics in terms of SU. The most important combinations are tilidine plus naloxone (14% of all SU in the Rx group), followed by codeine plus paracetamol (12%). The predominating single products in the Rx group are metamizole (36%) and tramadol (21%). Growth in the Rx group can be seen for both the combinations named and the single products.

The online version of the original article can be found under doi:10.1007/s10194-008-0046-6.
